Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jun 17 04:00PM ET
5.09
Dollar change
-0.55
Percentage change
-9.75
%
IndexRUT P/E- EPS (ttm)-3.56 Insider Own22.58% Shs Outstand35.87M Perf Week18.10%
Market Cap182.93M Forward P/E- EPS next Y-3.44 Insider Trans0.15% Shs Float27.83M Perf Month-60.17%
Income-127.27M PEG- EPS next Q-1.07 Inst Own88.06% Short Float42.86% Perf Quarter-67.71%
Sales0.00M P/S- EPS this Y-18.58% Inst Trans-10.86% Short Ratio9.01 Perf Half Y-63.77%
Book/sh3.77 P/B1.35 EPS next Y15.75% ROA-90.54% Short Interest11.93M Perf Year-86.18%
Cash/sh4.03 P/C1.26 EPS next 5Y- ROE-116.52% 52W Range3.61 - 38.84 Perf YTD-64.94%
Dividend Est.- P/FCF- EPS past 5Y-204.86% ROI-88.85% 52W High-86.89% Beta-0.49
Dividend TTM- Quick Ratio5.84 Sales past 5Y0.00% Gross Margin- 52W Low41.00% ATR (14)1.14
Dividend Ex-Date- Current Ratio5.84 EPS Y/Y TTM-10.86% Oper. Margin0.00% RSI (14)30.79 Volatility15.38% 10.26%
Employees103 Debt/Eq0.08 Sales Y/Y TTM- Profit Margin- Recom1.75 Target Price24.43
Option/ShortYes / Yes LT Debt/Eq0.06 EPS Q/Q-10.84% Payout- Rel Volume1.61 Prev Close5.64
Sales Surprise- EPS Surprise-9.64% Sales Q/Q- EarningsMay 02 AMC Avg Volume1.32M Price5.09
SMA20-45.72% SMA50-52.96% SMA200-62.30% Trades Volume2,133,137 Change-9.75%
Date Action Analyst Rating Change Price Target Change
Jun-11-24Downgrade Truist Buy → Hold
Jun-07-24Downgrade Barclays Overweight → Equal Weight $30 → $5
Apr-02-24Downgrade JP Morgan Overweight → Neutral $51 → $14
Feb-06-24Initiated Truist Buy $55
Jul-27-23Initiated Scotiabank Sector Outperform $41
Jun-26-23Downgrade Jefferies Buy → Hold
May-12-23Initiated Barclays Overweight $50
Mar-29-23Reiterated Oppenheimer Outperform $25 → $47
Mar-28-23Reiterated H.C. Wainwright Buy $37 → $44
Feb-24-23Initiated Citigroup Buy $20
Jun-17-24 09:00AM
Jun-11-24 11:34AM
09:06AM
Jun-07-24 04:23PM
08:16AM
07:22AM Loading…
07:22AM
06:17AM
04:25AM
Jun-06-24 04:05PM
01:14PM
Jun-03-24 04:05PM
May-30-24 09:12AM
May-02-24 10:54PM
04:05PM
May-01-24 04:10PM
11:02AM Loading…
Apr-19-24 11:02AM
Apr-01-24 04:10PM
01:52PM
09:02AM
09:00AM
Mar-07-24 02:52PM
Mar-06-24 03:04AM
Mar-01-24 04:16PM
Feb-19-24 03:18PM
Feb-18-24 03:41PM
Feb-08-24 04:19PM
Jan-09-24 11:02AM
Jan-08-24 09:00AM
Jan-02-24 04:05PM
Dec-12-23 09:27AM
09:25AM Loading…
Dec-11-23 09:25AM
Dec-09-23 05:30PM
Dec-08-23 09:00AM
Dec-07-23 09:15AM
Dec-05-23 08:30AM
Nov-27-23 08:30AM
Nov-16-23 08:30AM
Nov-08-23 04:05PM
Nov-02-23 09:05AM
Nov-01-23 05:58AM
Oct-31-23 01:19AM
Oct-30-23 04:01PM
Oct-18-23 10:13AM
Oct-17-23 08:30AM
Oct-05-23 09:40AM
08:30AM
Sep-28-23 08:30AM
Aug-31-23 08:30AM
Aug-23-23 12:26PM
Jul-31-23 04:01PM
Jul-24-23 09:00AM
Jul-13-23 10:08AM
Jun-26-23 10:54AM
Jun-23-23 09:54PM
Jun-20-23 04:30PM
Jun-05-23 06:44AM
May-18-23 06:39AM
May-14-23 09:43AM
May-11-23 08:39AM
May-02-23 04:01PM
May-01-23 08:30AM
Apr-27-23 07:02AM
Apr-23-23 09:28AM
Apr-19-23 02:42PM
08:30AM
Apr-13-23 04:30PM
09:00AM
Apr-07-23 07:44AM
Mar-30-23 02:35PM
Mar-29-23 11:15PM
12:01PM
11:24AM
06:30AM
Mar-28-23 04:02PM
08:00AM
Mar-23-23 08:00AM
Mar-21-23 09:40AM
Mar-20-23 08:50AM
Mar-02-23 08:30AM
Jan-20-23 11:30AM
Jan-18-23 11:27AM
Jan-17-23 08:00AM
Jan-09-23 08:00AM
Jan-04-23 09:00AM
Dec-14-22 04:30PM
05:44AM
Dec-12-22 08:00AM
Nov-14-22 08:12AM
Nov-11-22 08:30AM
Nov-07-22 04:27PM
Nov-03-22 09:19AM
Oct-31-22 08:00AM
Oct-27-22 08:00AM
Oct-14-22 09:00AM
Sep-22-22 09:30AM
Sep-20-22 07:30AM
Sep-19-22 12:01PM
Aug-26-22 01:13PM
08:30AM
Aug-01-22 04:05PM
Biomea Fusion, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic disorders, such as diabetes. It offers its lead product candidate, BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. The company was founded by Thomas Butler and Ramses Erdtmann in August 2017 and is headquartered in Redwood City, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Valle FrancoChief Financial OfficerJun 11 '24Buy4.4312,50955,36142,500Jun 12 04:30 PM